These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1365 related items for PubMed ID: 18701554

  • 1. Opportunities for improving medication use and monitoring in gout.
    Singh JA, Hodges JS, Asch SM.
    Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
    [Abstract] [Full Text] [Related]

  • 2. Serum urate levels and gout flares: analysis from managed care data.
    Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW.
    J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR.
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [Abstract] [Full Text] [Related]

  • 4. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [Abstract] [Full Text] [Related]

  • 5. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N, Kumar S, Stamp L, Gow P.
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [Abstract] [Full Text] [Related]

  • 6. Colchicine prescribing and safety monitoring in patients with gout.
    Ly J, Gow P, Dalbeth N.
    N Z Med J; 2007 Nov 09; 120(1265):U2808. PubMed ID: 18264188
    [Abstract] [Full Text] [Related]

  • 7. Quality of care for gout in the US needs improvement.
    Singh JA, Hodges JS, Toscano JP, Asch SM.
    Arthritis Rheum; 2007 Jun 15; 57(5):822-9. PubMed ID: 17530682
    [Abstract] [Full Text] [Related]

  • 8. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.
    Postgrad Med; 2014 Mar 15; 126(2):65-75. PubMed ID: 24685969
    [Abstract] [Full Text] [Related]

  • 9. Treatment of gout.
    Cohen MG.
    Intern Med J; 2011 Jan 15; 41(1a):70-1. PubMed ID: 21265967
    [No Abstract] [Full Text] [Related]

  • 10. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
    Arthritis Rheum; 2008 Nov 15; 59(11):1540-8. PubMed ID: 18975369
    [Abstract] [Full Text] [Related]

  • 11. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA, Fitz-Patrick D, Choi HK, Dalbeth N, Storgard C, Cravets M, Baumgartner S.
    Semin Arthritis Rheum; 2015 Oct 15; 45(2):174-83. PubMed ID: 26190562
    [Abstract] [Full Text] [Related]

  • 12. [Hyperuricemia and gout--treatment].
    Gröbner W, Walter-Sack I.
    Dtsch Med Wochenschr; 2002 Feb 01; 127(5):210-3. PubMed ID: 11821994
    [No Abstract] [Full Text] [Related]

  • 13. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
    Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW.
    Mayo Clin Proc; 2006 Jul 01; 81(7):925-34. PubMed ID: 16835972
    [Abstract] [Full Text] [Related]

  • 14. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Clin Pharmacol Ther; 2011 Sep 01; 90(3):392-8. PubMed ID: 21796116
    [Abstract] [Full Text] [Related]

  • 15. Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system.
    Mikuls TR, Curtis JR, Allison JJ, Hicks RW, Saag KG.
    J Rheumatol; 2006 Mar 01; 33(3):562-6. PubMed ID: 16482645
    [Abstract] [Full Text] [Related]

  • 16. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
    Panomvana D, Sripradit S, Angthararak S.
    J Clin Rheumatol; 2008 Feb 01; 14(1):6-11. PubMed ID: 18431090
    [Abstract] [Full Text] [Related]

  • 17. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.
    N Engl J Med; 2005 Dec 08; 353(23):2450-61. PubMed ID: 16339094
    [Abstract] [Full Text] [Related]

  • 18. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
    George M, Pullman-Mooar S, Hussain F, Schumacher HR.
    Arthritis Care Res (Hoboken); 2014 Aug 08; 66(8):1258-62. PubMed ID: 24376081
    [Abstract] [Full Text] [Related]

  • 19. The management of gout at an academic healthcare center in Beijing: a physician survey.
    Fang W, Zeng X, Li M, Chen LX, Schumacher HR, Zhang F.
    J Rheumatol; 2006 Oct 08; 33(10):2041-9. PubMed ID: 17014019
    [Abstract] [Full Text] [Related]

  • 20. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.
    Arthritis Care Res (Hoboken); 2012 Feb 08; 64(2):256-61. PubMed ID: 22052584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.